B
Bioniz
Biotechnology company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and cancer
About Bioniz
Bioniz Therapeutics is an emerging biopharmaceutical company focused on the discovery and development of first-in-class peptide therapeutics. These therapeutics are designed to selectively and simultaneously inhibit multiple cytokines, which are proteins that play a crucial role in the immune system. By targeting multiple cytokines, Bioniz aims to treat a range of immuno-inflammatory diseases and cancers more effectively.
Read full description
The company operates in the biopharmaceutical market, serving clients that include healthcare providers, research institutions, and pharmaceutical companies. Bioniz leverages its expertise in cytokine biology, gained through research conducted at the National Institutes of Health (NIH), to create innovative treatments that address the issue of cytokine redundancy. This redundancy refers to the immune system's use of multiple cytokines with overlapping functions to prevent failures from single cytokine malfunctions, making the immune system more resilient.
Bioniz's business model revolves around the development and commercialization of its peptide therapeutics. The company generates revenue through partnerships, licensing agreements, and potentially through the direct sale of its developed therapies once they receive regulatory approval.
At a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 24.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Bioniz.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Feb 2022 | $329M | $329M | Equillium | ↗ |
| ACQUISITION✓Exit | Jan 2020 | $0 | — | Almirall | — |
Growth signals
Latest recorded traffic for Bioniz is 540 monthly website visits. Bioniz's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A4 investors entered at this stage
Takeda
Takeda Ventures
Cota Capital
David Pyott
Other known investors4 additional known investors
Almirall
Equillium
National Institutes of Health
Broadway Angels
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bioniz on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bioniz’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.